A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
An Open-Label, Multicenter Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Brussel, Belgium
-
Wilrijk, Belgium
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with locally advanced or metastatic disease, any solid tumor except hepatocellular carcinoma (cancer of the liver), who have been relapsed or had progressive disease following standard of care treatment with chemotherapy prior to enrollment, or intolerant to prior standard of care treatment with chemotherapy
Exclusion Criteria:
- Patients with previous exposure to trabectedin
- Patients with cancer that has metastasized (spread) to the central nervous system
- Patients with known liver disease
- Patients who had a myocardial infarct (heart attack) within 6 months before enrollment or who have any other clinically significant or unstable medical condition as assessed by the Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Part 1
Patients will receive trabectedin+ketoconazole followed by trabectedin alone.
Each cycle will be will be separated by 21 days.
Patients will receive 6 total consecutive doses of ketoconazole.
Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
|
Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.
Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)
Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
|
|
EXPERIMENTAL: Part 2
Patients will receive 1 of 2 treatment sequences; Sequence 1: trabectedin+ketoconazole followed by trabectedin alone or Sequence 2: trabectedin alone followed by trabectedin+ketoconazole.
Each cycle will be separated by 21 days.
Patients will receive 15 total consecutive doses of ketoconazole.
Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
|
Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.
Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)
Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics of trabectedin
Time Frame: At protocol-specified time points for up to 8 days during each 21-day cycle in Sequence 1 and Sequence 2
|
At protocol-specified time points for up to 8 days during each 21-day cycle in Sequence 1 and Sequence 2
|
|
|
Pharmacokinetics of ketoconazole
Time Frame: 1 day during Sequence 1 or Sequence 2 after ketoconazole is coadministered with trabectedin
|
This will be measured when ketoconazole will be administered.
|
1 day during Sequence 1 or Sequence 2 after ketoconazole is coadministered with trabectedin
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients with adverse events
Time Frame: Time from 1st dose of trabectedin up to 30 days after the last dose of trabectedin
|
Time from 1st dose of trabectedin up to 30 days after the last dose of trabectedin
|
|
Findings from clinical laboratory evaluations
Time Frame: Time from 1st dose of trabectedin up to 30 days after the last dose of trabectedin
|
Time from 1st dose of trabectedin up to 30 days after the last dose of trabectedin
|
|
Findings from vital signs measurements
Time Frame: Time from 1st dose of trabectedin up to 30 days after the last dose of trabectedin
|
Time from 1st dose of trabectedin up to 30 days after the last dose of trabectedin
|
|
Findings from physical examinations
Time Frame: Time from 1st dose of trabectedin up to 30 days after the last dose of trabectedin
|
Time from 1st dose of trabectedin up to 30 days after the last dose of trabectedin
|
|
Evaluation of Survival data
Time Frame: At a time point to be determined by the sponsor at a later date
|
At a time point to be determined by the sponsor at a later date
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Neoplastic Processes
- Neoplasm Metastasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Dexamethasone
- Ketoconazole
- Trabectedin
Other Study ID Numbers
Other Study ID Numbers
- CR017539
- ET743OVC1003 (OTHER: Janssen Research & Development, LLC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.